GLP-1 access in the EU for Americans living abroad

If you're an American living in the European Union, you can access GLP-1 medications through EU-licensed telehealth without needing a US prescription or returning home. The regulatory framework is straightforward: you're a resident of an EU member state, and EU physicians can prescribe based on EU clinical guidelines.

This guide explains how the process works, what to expect, and why telehealth makes it accessible for expats, digital nomads, and Americans on long-term visas.

Who this is for

You're likely a candidate if you:

• Are a US citizen or dual citizen currently residing in an EU country
• Have a BMI above 27 with weight-related health conditions, or BMI above 30
• Have tried diet and exercise but want additional support
• Are on a D7, D8, digital nomad visa, or other long-term EU residency status
• Don't have established care with a local GP yet, or prefer remote assessment
• Want to avoid the cost and complexity of obtaining a US prescription while abroad

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) work by slowing gastric emptying and signalling satiety to the brain, reducing appetite and food intake. They're prescribed across the EU for weight management and metabolic health.

How EU telehealth assessment works

Unlike the US system, EU telehealth doesn't require you to be a returning patient or to have prior medical records transferred. The process is:

1. Initial assessment: You complete a detailed health questionnaire covering weight history, medications, cardiovascular risk, and lifestyle. This takes 10-15 minutes.

2. Physician review: An EU-licensed physician (registered in an EU member state) reviews your information, checks for contraindications, and may request additional details or a brief video consultation.

3. Prescription and dispensing: If approved, the prescription is issued under EU regulations and sent to a licensed pharmacy in your country of residence. You collect it locally or have it posted to you.

4. Follow-up: You'll have scheduled check-ins (typically at 4 weeks, 12 weeks, and ongoing) to monitor tolerability, adjust dosing, and track progress.

The entire first appointment typically takes 3-5 working days from submission to prescription. No US insurance is involved, and no US medical licence is required.

Timeline, cost, and what to expect

Timeline: Initial assessment to first dose in hand is usually 5-7 working days. Subsequent prescriptions are faster (2-3 days) once your baseline is established.

Cost: GLP-1 medications in the EU are typically EUR 80-200 per month depending on the agent, dosage, and your country's pharmacy pricing. Some EU countries have partial reimbursement if prescribed for type 2 diabetes; weight management is usually out-of-pocket. Telehealth consultation fees are typically EUR 40-80 per visit.

What to expect physically: Most people experience mild nausea in the first 1-2 weeks, which usually resolves. Appetite suppression is the intended effect. You'll be advised to start at a low dose and titrate gradually. Regular weigh-ins and symptom tracking are part of the protocol.

Medication availability: Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are available across the EU, though brand names and availability vary by country. Your physician will prescribe based on what's licensed and available in your specific member state.

GLP-1 access across the EU: regulatory clarity for Americans

Each EU member state has its own medicines regulator and prescribing guidelines, but the principle is consistent: if you're a legal resident, you can be prescribed by a licensed physician in that country.

• Germany, France, Netherlands, Spain, Italy: All have established telehealth frameworks and GLP-1 availability. Prescribing is routine for BMI >27 with comorbidities or BMI >30.
• Portugal, Greece, Poland: Growing telehealth infrastructure; GLP-1 access is available but may require slightly longer initial assessment.
• Nordic countries: Telehealth is well-established; GLP-1 prescribing is common and straightforward.

Your residency status (visa type, work permit, or citizenship) doesn't affect your ability to be prescribed by an EU physician. What matters is that you're physically resident in the EU and have a valid ID or residency document.

Important: You must be a resident of an EU member state to access this service. If you're planning to move to the EU or are in the process of relocating, you can begin the assessment once you have a local address and residency documentation.

Why telehealth is practical for expats

Finding a local GP as a new expat takes time. Telehealth removes that barrier: you don't need to wait for an appointment slot, navigate language barriers (most EU telehealth platforms offer English), or explain your medical history to a stranger in person. The assessment is thorough but asynchronous, fitting around your schedule.

You also avoid the cost and bureaucracy of obtaining a US prescription while abroad, then trying to fill it in Europe. EU prescriptions are recognised across member states, so if you move within the EU, your medication can follow you.

Next step

If you're an American resident in the EU and interested in GLP-1 for weight management, the first step is a confidential health assessment. This takes 15 minutes and gives you clarity on whether you're a candidate, what medication options suit you, and what the timeline and cost look like in your specific country.

For Americans residing in or relocating to the EU. We cannot serve US-resident patients.

Start your assessment at https://aetherahealth.eu/assessment?c=weight-management